Andrew Booth, Vice President at STEMCELL Technologies Joins the Advisory Board of Precision NanoSystems Inc.

Press Release

January 29, 2012

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, announced that Mr. Andrew Booth, Vice President & General Manager, Instrumentation Division at STEMCELL Technologies will join the Advisory Board. Andrew brings considerable experience in the development, manufacture and commercialization of research instrumentation into the life sciences market. Prior to joining STEMCELL Technologies, Andrew was based in London, UK on the Business Development team within GE Healthcare and held leadership roles for the mergers acquisitions and partnerships activity for GE Healthcare’s Life Sciences business and GE Healthcare’s Europe Middle East and Africa business. Andrew is also a graduate of GE’s Experienced Commercial Leadership Program, has an MBA from INSEAD in France and a degree in Engineering Physics from the University of British Columbia.

Precision NanoSystems CEO James Taylor, Ph.D. commented, “We are very excited to have Andrew join Precision NanoSystems. Andrew’s expertise and experience in the life sciences market will be extremely beneficial as the company moves its prototype products towards commercialization.”

Andrew Booth commented “I am delighted to join the Precision team as an advisor. I believe that their technology has the potential to significantly impact the development and use of nanoparticles as innovative tools to better understand the role of genes in causing and driving disease with the goal of one day developing targeted drug delivery and therapies. I look forward to contributing to Precision’s future success.”

About Precision NanoSystems, Inc.
At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.


Press Release

Precision NanoSystems, Inc. (PNI), a privately held biotechnology company developing proprietary microfluidic-based manufacturing technology for the use and development of cutting edge nanomedicines, today launched its commercial NanoAssemblrT...

Read More

News Article

Vancouver-based biotech firm Precision NanoSystems Inc. (PNI) has created a tabletop device that produces “self-assembling” molecules that carry drugs and gene therapies directly into the cells of the human body. Using the unique physic...

Read More